Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from AstraZeneca.

Cancer Summaries and Commentaries™: Report from San Diego on Advances in the Treatment of CLL

Release Date: December 23, 2020
Expiration Date: December 23, 2021

Activity Overview

This online activity is designed to update clinicians on data presented at the 62nd American Society of Hematology Annual Meeting & Exposition (ASH 2020), held December 5-8, 2020, in an all-virtual platform from San Diego, California. This information will help facilitate critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 4 abstracts from ASH 2020 that focus on chronic lymphocytic leukemia (CLL). For each abstract, a text summary of key clinical data is accompanied by perspectives from expert thought leaders who provide insights into how clinicians can apply these findings to their clinical practice to improve patient care.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from AstraZeneca.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This activity is directed toward medical oncologists and hematologists who are interested in the treatment of chronic lymphocytic leukemia (CLL). Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of patients with CLL will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the study design and rationale of recent clinical trials, evaluating emerging agents, alone or in combination, for the treatment of CLL
  • Describe results from recent trials that have evaluated emerging approaches for the treatment of CLL
  • Evaluate recent clinical trial evidence on novel therapeutic approaches in the context of evolving management paradigms for patients with CLL

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Jennifer R. Brown, MD, PhD
Jennifer R. Brown, MD, PhD
CLL Center
Dana- Faber Cancer Institute
Boston, Massachusetts
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Institute Physician
Department of Medical Oncology
Boston, MA

Disclosures: Grant and Research Support: Gilead, Loxo, Sun and Verastem. Consultant: Abbvie, Acerta, Astra-Zeneca, Beigene, Catapult, Eli Lilly, MEI Pharma, Novartis, Nextcea, Rigel, Pfizer. Other support: Invectys (Data Safety Monitoring Committee Service).

Nicole Lamanna, MD
Nicole Lamanna, MD
Associate Attending, Leukemia Service
Director, Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, NY

Disclosures: Grant/Research Support: Abbvie, AstraZeneca, Bei-Gene, Genentech, Juno, MingSight, Octapharma, Loxo, TG Therapeutics. Consultant: Abbvie, Bei-Gene, AstraZeneca, Celgene, Genentech, Janssen, Pharmacyclics.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By